PTX ASX logo
Prescient Therapeutics


This ASX biotech junior has some heavy cancer combating weaponry in its arsenal and is about to unleash several near term catalysts.

This company is at the forefront of cutting edge research that aims to better target drug therapies to improve outcomes for the patient — in terms of effectiveness in killing cancer cells, and reducing treatments’ toxic side-effects.

Trials of its first candidate in treating breast cancer, ovarian cancer and Acute Myeloid Leukaemia (AML), were well tolerated by patients, while effectively controlling or stabilising the disease.

Furthermore, trial of its second drug candidate in solid tumours also delivered promising results. The company is operating in a space which has already attracted the attention of billion dollar companies, including US$3.41 billion-capped (A$4.37B) Loxo Oncology Inc (NASDAQ:LOXO), the US$3.5 billion Array Biopharma which onsold its cancer drug to LOXO and the US$3.79 billion capped Blueprint Medicines Corp (NASDAQ:BPMC).

And one of the key people involved in the early development of the drug that helped LOXO to its mega valuation, is now one of the driving forces behind this company.

The information on this page should not be the only trigger for your investment decision. Click on the link below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

With no less than eight catalysts in the pipeline, all this company needs is one to be a company maker.

Expect healthy news flow for this biotech, with clinical trial and other developments for both PTX drugs providing potential share price catalysts and a culture of keen belief in its product.

PTX will be one to watch.

Australian ASX Small Cap stocks | Why is Australia’s leading small cap publication

Founded seven years ago, is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise. provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more. is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!